Form 4: MBX Biosciences CEO Exercises Stock Options
Insider Transaction Report
MBX Biosciences President & CEO P. Kent Hawryluk exercised options to acquire 182,859 shares of common stock at $3.25 per share.
Summary
- P. Kent Hawryluk, President & CEO and Director of MBX Biosciences, Inc. (MBX), exercised stock options on October 24, 2025.
- Hawryluk acquired 182,859 shares of MBX Common Stock at an exercise price of $3.25 per share.
- Following this transaction, Hawryluk directly owns 664,256 shares of Common Stock.
- An additional 468,277 shares are indirectly owned by the P. Kent Hawryluk Revocable Trust, of which Hawryluk serves as trustee.
- The exercised options were part of a grant where 1/48th of the shares vested in substantially equal monthly installments from November 7, 2022, with full vesting scheduled for November 7, 2026.
- The options included an early-exercise provision, allowing them to become exercisable in full on November 7, 2022, subject to an Issuer right of repurchase.
- After the exercise, Hawryluk directly holds 129,708 derivative securities (stock options).
Sentiment
Score: 7
Explanation: The President & CEO exercising a significant number of stock options suggests confidence in the company's future performance and potential for stock price appreciation, which is generally a positive signal for investors.
Positives
- Increased direct ownership by a key executive (President & CEO, Director) signals confidence in the company's future prospects.
- The exercise of options at $3.25 per share suggests a belief that the current or future market price will be higher than the exercise price, indicating potential for stock appreciation.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Shares are indirectly held by the P. Kent Hawryluk Revocable Trust, dated January 25, 2011, of which the reporting person serves as trustee. The reporting person disclaims beneficial ownership except to the extent of any pecuniary interest therein.
Stakeholder Impact
- Shareholders: Increased insider ownership may be viewed positively, signaling management's alignment with shareholder interests and confidence in the company's future.
Next Steps
- Continued vesting of remaining stock options until full vesting on November 7, 2026.
Key Dates
| Date | Description |
|---|---|
| 2011-01-25 | Date of the P. Kent Hawryluk Revocable Trust establishment. |
| 2022-11-07 | Date when the stock option began vesting monthly and became exercisable in full pursuant to an early-exercise provision. |
| 2025-10-24 | Date of the reported transaction where stock options were exercised. |
| 2025-10-28 | Date the Form 4 was signed by the attorney-in-fact. |
| 2026-11-07 | Date when the stock option is scheduled to be fully vested. |
| 2032-11-06 | Expiration date of the stock option. |
Keywords
MBX Biosciences, P. Kent Hawryluk, Stock Option Exercise, Insider Transaction, Form 4, CEO, Director, Equity Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.